NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that ...
The Sunday Guardian Live on MSN
Word of the day 'acumen': Know the meaning, origin, phonetic, IPA & more
India, March 27 -- Daily practice of learning one new word will enhance your language abilities and boost your power to ...
Enrollment complete for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease Anticipate topline results in late 2026 Topline results from the ...
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Lead clinical candidate IND filing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results